Annual report [Section 13 and 15(d), not S-K Item 405]

Segment Information

v3.25.1
Segment Information
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Segment Information

16. Segment Information

The Company views its operations and manages its business as one operating and reportable segment, which is the business of developing protein kinase inhibitor therapeutics. Consistent with the operational structure, the Chief Executive Officer, as the chief operating decision maker (“CODM”), manages and allocates resources on a consolidated basis using consolidated net income (loss) as a measure of profit/loss for the single reportable segment. This decision making process reflects the way in which the financial

information is regularly reviewed and used by the CODM to evaluate performance, set operational targets, forecast future financial results, and allocate resources.

 

 

Year ended December 31,

 

 

2024

 

 

2023

 

Revenues and other income

 

 

 

 

 

Grant income

$

—

 

 

$

260,501

 

Costs and expenses:

 

 

 

 

 

Research and development (excluding share-based compensation) expense:

 

 

 

 

 

PAH

 

1,672,869

 

 

 

—

 

PD

 

9,333,359

 

 

 

9,036,750

 

Other programs

 

1,512,151

 

 

 

4,421,520

 

Selling, general and administrative (excluding share-based compensation)

 

7,930,072

 

 

 

6,391,875

 

Share-based compensation expense

 

8,140,617

 

 

 

500,148

 

Total costs and expenses

 

28,589,068

 

 

 

20,350,293

 

Loss from operations

 

(28,589,068

)

 

 

(20,089,792

)

Interest income

 

1,069,182

 

 

 

1,060,909

 

Net loss

$

(27,519,886

)

 

$

(19,028,883

)